CLRB - セレクタ・バイオサイエンシ―ズ （Cellectar Biosciences Inc.）

The following slide deck was published by Cellectar Biosciences, Inc.

Cellectar Biosciences press release (CLRB): FY GAAP EPS of -$4.05 misses by $0.74.As of December 31, 2022, the company had cash and cash equivalents of $19.9 million, compared to…

FLORHAM PARK, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization…

Cellectar Biosciences Inc. (NASDAQ:CLRB) marked $1.56 per share on Tuesday, up from a previous closing price of $1.50. While Cellectar Biosciences Inc. has overperformed by 4.00%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CLRB fell by -67.49%, with highs and lows ranging from $7.90 to […]

FLORHAM PARK, N.J., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it has hired Andrei Shustov, M.D., as its new Senior Vice President, Medical reporting to Mr. James Caruso, president and CEO. In this role, Dr. Shustov will lead and provide oversight on all aspects of the Company’s clinical development program, medical affairs, and medical communications.

The following slide deck was published by Cellectar Biosciences, Inc.

https://www.investing.com/news/pro/cellectar-biosciences-pt-lowered-to-25-at-roth-capital-432SI-2931444

Cellectar Biosciences (NASDAQ: CLRB ) reported its Q3 earnings results on Thursday, November 3, 2022 at 08:30 AM. Here''s what investors need to know about the announcement. Earnings Cellectar Biosciences missed estimated earnings by 5.79%, reporting … Full story available on Benzinga.com

Cellectar Biosciences press release (CLRB): Q3 GAAP EPS of -$1.28 misses by $0.04.As of September 30, 2022, the company had cash and cash equivalents of $17.8 million, compared to…

Cellectar Biosciences (CLRB) shares fell ~18% premarket on announcing concurrent registered direct and private placement offerings of ~$10.7M priced at-the-market under Nasdaq…

The following slide deck was published by Cellectar Biosciences, Inc.

https://www.investing.com/news/pro/cellectar-biosciences-pt-lowered-to-25-at-roth-capital-432SI-2931444

Cellectar Biosciences (NASDAQ: CLRB ) reported its Q3 earnings results on Thursday, November 3, 2022 at 08:30 AM. Here''s what investors need to know about the announcement. Earnings Cellectar Biosciences missed estimated earnings by 5.79%, reporting … Full story available on Benzinga.com

Cellectar Biosciences press release (CLRB): Q3 GAAP EPS of -$1.28 misses by $0.04.As of September 30, 2022, the company had cash and cash equivalents of $17.8 million, compared to…

Cellectar Biosciences (CLRB) shares fell ~18% premarket on announcing concurrent registered direct and private placement offerings of ~$10.7M priced at-the-market under Nasdaq…